医学临床研究
  2025年6月16日 星期一           首 页    |    期刊简介    |    编委会    |    投稿指南    |    期刊订阅    |    广告合作    |    留言板    |    联系我们    |    English
医学临床研究  2025, Vol. 42 Issue (4): 638-641    DOI: 10.3969/j.issn.1671-7171.2025.04.022
  论著 本期目录 | 过刊浏览 | 高级检索 |
舍曲林与帕罗西汀治疗脑卒中后抑郁症对患者神经递质功率及抑郁情绪的影响比较
申贵玉a*黄焱a, 谢清芳a, 王能琨a, 黄海东b
上海市宝山区精神卫生中心:a.精神科;b.门诊,上海 201900
Comparison of the Effects of Sertraline and Paroxetine on Neurotransmitter Power and Depressive Mood in Patients with Post-Stroke Depression
SHEN Guiyu, HUANG Yan, XIE Qingfang, et al
Shanghai Baoshan District Mental Health Center, Shanghai 201900
全文: PDF (1181 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 【目的】比较舍曲林与帕罗西汀治疗脑卒中后抑郁症对患者神经递质功率及抑郁情绪的影响。【方法】140例脑卒中后抑郁症患者,根据治疗方法不同分为A组、B组,每组70例。两组均给予常规对症治疗,A组同时给予舍曲林治疗,B组同时给予帕罗西汀治疗。比较两组治疗前后汉密尔顿抑郁量表-24项版(HAMD)评分、美国国立卫生研究院卒中量表(NIHSS)评分、Barthel指数(BI)评分、Asberg抗抑郁药不良反应量表(SERS)评分;比较两组治疗前后γ-氨基丁酸(GABA)、乙酰胆碱(Ach)、谷氨酸(Glu)、去甲肾上腺素(NE)、白细胞介素-2(IL-2)、肿瘤坏死因子-α(TNF-α)水平及两组疗效。【结果】A组总有效率为92.86%(65/70),高于B组的80.00%(56/70)(P<0.05)。治疗4周和8周后,两组HAMD评分逐渐下降(P<0.05),A组HAMD评分低于B组(P<0.05)。治疗4周和8周后,两组GABA、Ach、Glu、NE水平和BI评分逐渐上升(P<0.05),A组GABA、Ach、Glu、NE水平和BI评分高于B组(P<0.05)。治疗4周和8周后,两组患者IL-2、TNF-α水平和NIHSS评分逐渐下降(P<0.05),且A组IL-2、TNF-α水平和NIHSS评分低于B组(P<0.05)。A组治疗4周和8周后SERS评分均低于B组(P<0.05)。【结论】舍曲林治疗脑卒中后抑郁症患者,可有效改善患者负性情绪,提高神经递质功率,减少神经功能损伤,且安全性高。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
申贵玉黄焱
谢清芳
王能琨
黄海东
关键词 卒中抑郁症舍曲林帕罗西汀    
Abstract:【Objective】To compare the effects of sertraline and paroxetine on neurotransmitter power and depression in patients with post-stroke depression.【Methods】A total of 140 patients with post-stroke depression were divided into two groups according to different treatment methods, with 70 cases in each group. Both groups were given conventional symptomatic treatment, while group A was also given sertraline treatment, while group B was given paroxetine treatment. The changes in Hamilton Depression Rating Scale-24 (HAMD) score, National Institutes of Health Stroke Scale (NIHSS) score, Barthel Index (BI) score, Asberg Antidepressant Side Effects Rating Scale (SERS) score before and after treatment were compared between the two groups. The changes in gamma-aminobutyric acid (GABA), acetylcholine (Ach), glutamate (Glu), norepinephrine (NE), interleukin-2 (IL-2), tumor necrosis factor-α (TNF-α) levels before and after treatment, as well as the efficacy of the two groups, were also compared.【Results】The total effective rate of group A was 92.86% (65/70), which was higher than that of group B (80.00%,56/70) (P<0.05). After 4 weeks and 8 weeks of treatment, the HAMD scores of the two groups gradually decreased (P<0.05), and the HAMD score of group A was lower than that of group B (P<0.05). After 4 weeks and 8 weeks of treatment, the levels of GABA, Ach, Glu, NE, and BI scores gradually increased in both groups (P<0.05), while the GABA, Ach, Glu, NE, and BI scores in group A were higher than those in group B (P<0.05). After 4 weeks and 8 weeks of treatment, the IL-2, TNF-α, and NIHSS scores gradually decreased in both groups (P<0.05), and the IL-2, TNF-α, and NIHSS scores in group A were lower than those in group B (P<0.05). The SERS scores of group A were lower than those of group B after 4 weeks and 8 weeks of treatment (P<0.05).【Conclusion】Sertraline treatment for post-stroke depression can effectively improve patients' negative emotions, increase neurotransmitter power, reduce neural functional damage, and have high safety.
Key wordsStroke    Depressive Disorder    Sertraline    Paroxetine
收稿日期: 2023-04-25     
中图分类号:  R743.3  
通讯作者: *E-mail:kjghk8038@163.com   
引用本文:   
申贵玉黄焱, 谢清芳, 王能琨, 黄海东. 舍曲林与帕罗西汀治疗脑卒中后抑郁症对患者神经递质功率及抑郁情绪的影响比较[J]. 医学临床研究, 2025, 42(4): 638-641.
SHEN Guiyu, HUANG Yan, XIE Qingfang, et al. Comparison of the Effects of Sertraline and Paroxetine on Neurotransmitter Power and Depressive Mood in Patients with Post-Stroke Depression. JOURNAL OF CLINICAL RESEARCH, 2025, 42(4): 638-641.
链接本文:  
http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2025.04.022     或     http://journal07.magtech.org.cn/yxlcyj/CN/Y2025/V42/I4/638
版权所有 © 2013 医学临床研究杂志社  湘ICP备13012052号-1
办公地址:湖南省长沙市芙蓉区新军路43号煤炭大院主办公楼6楼621、623、632、636室 邮编:410011 电话(传真):0731-84824007 E-mail:jcr_cs.hn@vip.163.com
技术支持:北京玛格泰克科技发展有限公司 技术支持:support@magtech.com.cn